EUVIMEDEUVIMED entdecken
Open Access

The third symposium on treatment-induced neuroendocrine prostate cancer: insights and future directions

Yuzhuo Wang iD, Joshua Scurll, Itzel Astiazarán Rascón, Cassandra Cui, Yuchao Ni, Ace Mingchen Shi, Priyadarsini Gangadharannambiar, Yu Wang, Shusuke Akamatsu, Himisha Beltran, Michael Cox, Francesco Crea iD und 13 weitere

Epigenomics · 2024

DOI: 10.1080/17501911.2024.2391729 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Epigenomics, 2024. Verfasst von Yuzhuo Wang und 24 weiteren Autor:innen. Beteiligte Einrichtung: Vancouver Prostate Centre, Vancouver, BC, V6H 3Z6, Canada. Hauptthemen laut MEDLINE: Prostatic Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Mr. Jmaes Killam, Vancouver Prostate Centre, Institute of Cancer Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neuroendocrine prostate cancer (NEPC) is a rare and aggressive subtype of prostate cancer (PCa), emerging from advanced treatments and characterized by loss of androgen receptor (AR) signaling and neuroendocrine features, leading to rapid progression and treatment resistance. The third symposium on treatment-induced NEPC, held from 21 to 23 June 2024, at Harrison Hot Springs Resort, BC, Canada, united leading global researchers and clinicians. Sponsored by the Vancouver Prostate Centre (VPC), Canadian Institute of Health Research, Prostate Cancer Foundation Canada and Pharma Planter Inc, the event focused on the latest NEPC research and innovative treatment strategies. Co-chaired by Drs. Yuzhuo Wang and Martin Gleave, the symposium featured sessions on NEPC's historical context, molecular pathways, epigenetic regulation and the role of the tumor microenvironment and metabolism in its progression. Keynotes from experts like Dr. Himisha Beltran and Dr. Martin Gleave highlighted the complexity of NEPC. The Emerging Talent session showcased new research, pointing to the future of NEPC treatment. The symposium concluded with a consensus on the need for early detection, targeted therapies and personalized medicine to effectively combat NEPC, emphasizing the importance of global collaboration in advancing NEPC understanding and treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsHumansMaleCarcinoma, NeuroendocrineReceptors, AndrogenTumor MicroenvironmentEpigenesis, GeneticNeuroendocrine Tumors

Substanzen

Receptors, Androgen

Autor:innen und Institutionen

  • Vancouver Prostate Centre, Vancouver, BC, V6H 3Z6, Canada.
  • Department of Urologic Sciences, Faculty of Medicine, University of British Columbia, Vancouver, BC, V5Z 1M9, Canada.
  • BC Cancer Research Institute, BC Cancer, Vancouver, BC, V5Z 1L3, Canada.
  • Open University, School of Life Health & Chemical Sciences, Milton Keynes, MK7 6AA, UK.
  • Department of Urology, Nagoya University Graduate School of Medicine, Aichi, 466-8550, Japan.
  • Dana-Farber Cancer Institute, Boston, MA 02215, USA.

ORCID-Profile: Yuzhuo Wang, Francesco Crea

Förderung

  • Mr. Jmaes Killam
  • Vancouver Prostate Centre
  • Institute of Cancer Research
  • NCI NIH HHS
  • PCF Canada
  • Pharma Planter Inc.

Zitieren

APA

Wang, Y., Scurll, J., Rascón, I. A., Cui, C., Ni, Y., Shi, A. M., Gangadharannambiar, P., Wang, Y., Akamatsu, S., Beltran, H., Cox, M., Crea, F., Daugaard, M., Dong, X., Haffner, M., He, H., Jachetti, E., Kyprianou, N., Li, B., …, & Gleave, M. E. (2024). The third symposium on treatment-induced neuroendocrine prostate cancer: insights and future directions. Epigenomics. https://doi.org/10.1080/17501911.2024.2391729

Vancouver

Wang Y, Scurll J, Rascón IA, Cui C, Ni Y, Shi AM, et al. The third symposium on treatment-induced neuroendocrine prostate cancer: insights and future directions. Epigenomics. 2024. doi:10.1080/17501911.2024.2391729

BibTeX
@article{Wang2024,
  author = {Wang, Yuzhuo and Scurll, Joshua and Rascón, Itzel Astiazarán and Cui, Cassandra and Ni, Yuchao and Shi, Ace Mingchen and Gangadharannambiar, Priyadarsini and Wang, Yu and Akamatsu, Shusuke and Beltran, Himisha and Cox, Michael and Crea, Francesco and Daugaard, Mads and Dong, Xuesen and Haffner, Michael and He, Hansen and Jachetti, Elena and Kyprianou, Natasha and Li, Benyi and Ong, Christopher E and Rickman, David S and Sen, Triparna and Zhu, Helen He and Zoubeidi, Amina and Gleave, Martin E},
  title = {The third symposium on treatment-induced neuroendocrine prostate cancer: insights and future directions},
  journal = {Epigenomics},
  year = {2024},
  doi = {10.1080/17501911.2024.2391729}
}
Kostenlos starten →